8-K: Quanterix Reports Q4 & FY25 Results, Eyes 2026 Cash Flow Breakeven

Quanterix announced its fourth quarter and full year 2025 financial results, reporting revenue stabilization and significant progress towards achieving cash flow breakeven in the second half of 2026.

Summary

• Fourth quarter 2025 revenue was $43.9 million, a 25% increase compared to $35.2 million in the prior year.
• Full year 2025 revenue was $138.9 million, a 1% increase compared to $137.4 million in the prior year.
• Adjusted cash usage for Q4 2025 was $3.0 million, and for the full year 2025 was $30.9 million.
• The company ended the fourth quarter with $121.6 million in cash, cash equivalents, marketable securities, and restricted cash, exceeding its guidance of $120 million.
• Quanterix has implemented $74 million of its $85 million cost synergy target related to the Akoya acquisition, with 94% of integration milestones complete.
• A 510(k) premarket notification was submitted to the FDA in January 2026 for its multi-analyte algorithmic blood test for Alzheimer's disease.
• The Centers for Medicare & Medicaid Services (CMS) established a reimbursement rate of $897 for Quanterix's LucentAD Complete test.
• 13 new assays were launched in 2025, including two new Simoa tau assays and two new Phenocode Discovery panels.
• Material weaknesses in internal control over financial reporting have been remediated.
• For 2026, the company expects revenues of $169 million to $174 million, GAAP gross margin of 45-49%, and adjusted gross margin (non-GAAP) of 49-53%.
• Quanterix anticipates achieving cash flow breakeven performance in the second half of 2026 and expects to exit the year with approximately $100 million in cash and no debt.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with cautious optimism. While Q4 revenue beat expectations and strategic milestones in Alzheimer's diagnostics are promising, the significant decline in full-year profitability metrics and minimal revenue growth for 2025 indicate ongoing challenges, tempered by a clear path to cash flow breakeven in 2026.

Positives

• Fourth quarter 2025 revenue increased 25% year-over-year to $43.9 million, exceeding expectations.
• The company ended 2025 with $121.6 million in cash, cash equivalents, marketable securities, and restricted cash, surpassing its guidance of $120 million.
• Adjusted cash usage was significantly reduced to $3.0 million in Q4 2025.
• Quanterix has implemented $74 million of its $85 million cost synergy target from the Akoya acquisition, with 94% of integration milestones complete.
• A 510(k) premarket notification was submitted to the FDA in January 2026 for its multi-analyte Alzheimer's disease blood test, marking a significant milestone.
• CMS established a favorable reimbursement rate of $897 for the LucentAD Complete test, facilitating claims submissions and supporting broader adoption.
• 13 new assays were launched in 2025, including two new Simoa tau assays and two new Phenocode Discovery panels, demonstrating continued product innovation.
• Material weaknesses in internal control over financial reporting have been remediated, providing a stronger foundation for growth.
• The company anticipates achieving cash flow breakeven performance in the second half of 2026.
• Quanterix expects to exit 2026 with approximately $100 million in cash and no debt.

Negatives

• GAAP gross margin decreased to 45.7% in Q4 2025 from 63.0% in Q4 2024, and to 46.8% for FY 2025 from 60.5% in FY 2024.
• Adjusted gross margin (non-GAAP) decreased to 50.0% in Q4 2025 from 57.7% in Q4 2024, and to 47.3% for FY 2025 from 54.6% in FY 2024.
• Adjusted EBITDA (non-GAAP) loss widened to $7.9 million in Q4 2025 from $5.9 million in Q4 2024, and significantly to $44.9 million for FY 2025 from $23.6 million in FY 2024.
• Net loss for FY 2025 was $(107.150) million, a substantial increase from $(38.531) million in FY 2024.
• Net loss per common share, basic and diluted, was $(2.51) for FY 2025, compared to $(1.00) for FY 2024.
• Full year 2025 total revenue growth was only 1%, and adjusted revenue decreased 19% year-over-year.
• Simoa revenue decreased 23% year-over-year for FY 2025, and Spatial Biology revenue decreased 15% year-over-year for FY 2025.
• A diagnostics development agreement with unfavorable terms, assumed as part of the Akoya acquisition, was terminated in Q1 2026.

Risks

• Risks related to the impact of changes in U.S. government policies, including tariffs and reductions in federal research funding.
• Risks associated with the anticipated timing for launch of, and features of, Quanterix's next-generation instruments to upgrade its existing platforms.
• Risks related to Quanterix's ability to improve existing diagnostics and develop new diagnostic tests and tools.
• Risks related to Quanterix's ability to successfully penetrate the diagnostics market.
• Risks related to Quanterix's ability to retain and expand its customer base and achieve sufficient market acceptance of its products.
• Risks related to the ability of Quanterix's contract manufacturers and suppliers to reliably and consistently manufacture and supply its instruments.
• Risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisitions of Emission, Inc. and Akoya Biosciences Inc.
• Risk that integrating Quanterix's business with that of Akoya could be more difficult, costly or time-consuming than expected.
• Risks that Quanterix's estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect.
• Risks related to Quanterix's ability to maintain effective internal control over financial reporting and disclosure controls and procedures.
• Risks related to defects or other quality issues in Quanterix's products that could lead to unforeseen costs, product recalls, adverse regulatory actions, negative publicity and litigation.

Future Outlook

Quanterix expects full year 2026 revenues between $169 million and $174 million, representing 0-3% growth after accounting for a terminated diagnostics development agreement. GAAP gross margin is projected to be 45-49%, and adjusted gross margin (non-GAAP) between 49% and 53%. The company anticipates achieving cash flow breakeven performance in the second half of 2026 and expects to exit the year with approximately $100 million in cash and no debt.

Management Comments

• "I am thrilled to be joining Quanterix at a time when the company is well-positioned to deliver long-term growth." Everett Cunningham, President & CEO.
• "During the fourth quarter, we exceeded our revenue expectations, we continued to move the company closer to profitability, and we achieved key milestones in our Alzheimer's Diagnostics business." Everett Cunningham, President & CEO.
• "With most of the major integration milestones now behind us, our focus now turns to driving consistent profitable revenue growth and achieving cash flow breakeven performance in 2026." Everett Cunningham, President & CEO.
• "My immediate focus is on spending time with the Quanterix team, customers, shareholders, and partners as I evaluate the Company's strategy and future potential and ensure that we have the resources, support and capabilities to deliver on our operational priorities." Everett Cunningham, President & CEO.
• "I am extremely optimistic for what the future holds for Quanterix." Everett Cunningham, President & CEO.

Industry Context

StockSavvy.ai notes that Quanterix operates in the highly competitive and rapidly evolving ultra-sensitive biomarker detection and spatial biology markets. The company's focus on Alzheimer's diagnostics, particularly with the FDA 510(k) submission and CMS reimbursement rate for its multi-analyte blood test, positions it to capitalize on the growing demand for early and non-invasive diagnostic tools for neurodegenerative diseases. The integration of Akoya Biosciences' spatial biology capabilities further diversifies its offerings, aligning with the broader industry trend towards integrated multi-omic approaches in precision medicine.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for improved financial performance and cash flow breakeven in 2026, but current profitability challenges persist. Strategic progress in Alzheimer's diagnostics could drive long-term value.
• Customers: Continued product innovation with 13 new assays and advancements in Alzheimer's diagnostics (FDA submission, CMS reimbursement) enhance product offerings and accessibility.
• Employees: Integration of Akoya Biosciences involves consolidation and potential restructuring, but the focus on synergy realization aims for a more efficient combined entity.
• Payors: CMS reimbursement rate of $897 for LucentAD Complete test provides a clear pricing structure, facilitating coverage decisions.

Next Steps

• Complete remaining cost synergies by the end of Q1 2026.
• Complete 3 ongoing clinical utility studies by Q3 2026 to support payor engagement and drive reimbursement for Alzheimer's diagnostics.
• Continue to build the Order-to-Cash lab infrastructure supporting the dedicated commercial organization for Alzheimer's testing.
• Drive consistent profitable revenue growth in 2026.
• Achieve cash flow breakeven performance in the second half of 2026.
• Everett Cunningham (new CEO) will evaluate the company's strategy and future potential.

Key Dates

Recommendation

While Quanterix demonstrated strong Q4 revenue growth and made significant progress in Alzheimer's diagnostics and cost synergies, the full-year financial performance shows considerable declines in gross margins and a widening adjusted EBITDA loss. The path to cash flow breakeven in 2026 is a positive forward-looking statement, but the company needs to demonstrate consistent profitable revenue growth and successful integration of acquisitions to warrant a stronger buy recommendation. The stock is a hold as investors await further execution on these strategic initiatives and a clearer trend towards sustained profitability.

Keywords

Quanterix, QTRX, financial results, earnings, Q4 2025, FY 2025, Alzheimer's diagnostics, Simoa, Akoya Biosciences, spatial biology, biomarker detection, FDA 510(k), CMS reimbursement, cost synergies, cash flow breakeven, diagnostics, life sciences, medical devices